New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:16 EDTJAZZJazz consensus expectations too low, says Lazard Capital
Lazard Capital believes consensus expectations for Jazz Pharmaceuticals are too low following the company's Xyrem price increase last week. The firm keeps a Buy rating on the stock with an $87 price target.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
12:49 EDTJAZZOn The Fly: Midday Wrap
Subscribe for More Information
12:09 EDTJAZZFlamel Technologies plunges after Jazz gets favorable patent ruling
Subscribe for More Information
January 12, 2015
13:21 EDTJAZZJazz Pharmaceuticals says 2015 will include top, bottom line growth
Subscribe for More Information
13:17 EDTJAZZJazz sees 2014 Erwinaze sales at upper end of range
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use